{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Skin and subcutaneous tissue disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Noncardiac chest pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Sciatic pain"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Toxicity and tolerability of pembrolizumab in subjects with refractory GCTs. All grade 3 and higher adverse events are reported.","groups":[{"description":"Pembrolizumab\n\nPembrolizumab: 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.","id":"OG000","title":"Experimental Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Every week while patient is receiving pembrolizumab, assessed for up to 52 weeks","title":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability Using Common Terminology Criteria for Adverse Events (CTCAE) V4.","type":"SECONDARY","unitOfMeasure":"Participants"}